FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022282235> ?p ?o ?g. }

• W2022282235 endingPage "1574" @default.
• W2022282235 startingPage "1569" @default.
• W2022282235 abstract "BACKGROUND The objective of this study was to assess the biologic activity of rosiglitazone, a peroxisome proliferator-activated receptor γ agonist that has been approved to treat type 2 diabetes, in men with recurrent prostate carcinoma using change in prostate specific antigen (PSA) doubling time (PSADT) as the primary outcome variable. METHODS Men with histologically confirmed prostate carcinoma, no recent hormone therapy, a rising serum PSA level after radical prostatectomy and/or radiation therapy, and no radiographic evidence of metastases were assigned randomly to receive either oral rosiglitazone (4 mg twice daily) or placebo. The treatment was continued until the men developed disease progression or adverse effects. A positive outcome was defined as a posttreatment PSADT > 150% the baseline PSADT and no new metastases. RESULTS One hundred six men were enrolled. The median treatment duration was 315 days for men in the placebo group and 338 days for men in the rosiglitazone group (P = 0.28). Forty percent of men in the in the placebo group and 38% of men in the rosiglitazone group had a posttreatment PSADT > 150% of the baseline PSADT and no new metastases (P = 1.00). In exploratory analyses, the rate of a positive outcome remained higher than expected in the placebo group, even when a positive outcome was redefined using more stringent criteria. The time to disease progression was similar between the groups. CONCLUSIONS Rosiglitazone did not increase PSADT or prolong the time to disease progression more than placebo in men with a rising PSA level after radical prostatectomy and/or radiation therapy. The unexpected discordance between baseline and posttreatment PSADT in the placebo group reinforced the importance of randomized controlled trials in this setting. Cancer 2004. © 2004 American Cancer Society." @default.
• W2022282235 created "2016-06-24" @default.
• W2022282235 creator A5004802831 @default.
• W2022282235 creator A5007578304 @default.
• W2022282235 creator A5017925159 @default.
• W2022282235 creator A5018292930 @default.
• W2022282235 creator A5020223699 @default.
• W2022282235 creator A5022918796 @default.
• W2022282235 creator A5023563011 @default.
• W2022282235 creator A5039147214 @default.
• W2022282235 creator A5045746656 @default.
• W2022282235 creator A5054383262 @default.
• W2022282235 date "2004-01-01" @default.
• W2022282235 modified "2023-10-12" @default.
• W2022282235 title "Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy" @default.
• W2022282235 cites W1647126819 @default.
• W2022282235 cites W1970400785 @default.
• W2022282235 cites W1982149138 @default.
• W2022282235 cites W2003699768 @default.
• W2022282235 cites W2053571455 @default.
• W2022282235 cites W2054279868 @default.
• W2022282235 cites W2058680827 @default.
• W2022282235 cites W2071879495 @default.
• W2022282235 cites W2090653702 @default.
• W2022282235 cites W2131669718 @default.
• W2022282235 cites W2141283971 @default.
• W2022282235 cites W2155679349 @default.
• W2022282235 cites W4293168096 @default.
• W2022282235 doi "https://doi.org/10.1002/cncr.20493" @default.
• W2022282235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15468186" @default.
• W2022282235 hasPublicationYear "2004" @default.
• W2022282235 type Work @default.
• W2022282235 sameAs 2022282235 @default.
• W2022282235 citedByCount "121" @default.
• W2022282235 countsByYear W20222822352012 @default.
• W2022282235 countsByYear W20222822352013 @default.
• W2022282235 countsByYear W20222822352014 @default.
• W2022282235 countsByYear W20222822352015 @default.
• W2022282235 countsByYear W20222822352016 @default.
• W2022282235 countsByYear W20222822352017 @default.
• W2022282235 countsByYear W20222822352018 @default.
• W2022282235 countsByYear W20222822352019 @default.
• W2022282235 countsByYear W20222822352020 @default.
• W2022282235 countsByYear W20222822352021 @default.
• W2022282235 countsByYear W20222822352022 @default.
• W2022282235 countsByYear W20222822352023 @default.
• W2022282235 crossrefType "journal-article" @default.
• W2022282235 hasAuthorship W2022282235A5004802831 @default.
• W2022282235 hasAuthorship W2022282235A5007578304 @default.
• W2022282235 hasAuthorship W2022282235A5017925159 @default.
• W2022282235 hasAuthorship W2022282235A5018292930 @default.
• W2022282235 hasAuthorship W2022282235A5020223699 @default.
• W2022282235 hasAuthorship W2022282235A5022918796 @default.
• W2022282235 hasAuthorship W2022282235A5023563011 @default.
• W2022282235 hasAuthorship W2022282235A5039147214 @default.
• W2022282235 hasAuthorship W2022282235A5045746656 @default.
• W2022282235 hasAuthorship W2022282235A5054383262 @default.
• W2022282235 hasConcept C121608353 @default.
• W2022282235 hasConcept C126322002 @default.
• W2022282235 hasConcept C126894567 @default.
• W2022282235 hasConcept C141071460 @default.
• W2022282235 hasConcept C142724271 @default.
• W2022282235 hasConcept C170493617 @default.
• W2022282235 hasConcept C204787440 @default.
• W2022282235 hasConcept C27081682 @default.
• W2022282235 hasConcept C2776235491 @default.
• W2022282235 hasConcept C2779466945 @default.
• W2022282235 hasConcept C2780152017 @default.
• W2022282235 hasConcept C2781406297 @default.
• W2022282235 hasConcept C509974204 @default.
• W2022282235 hasConcept C71924100 @default.
• W2022282235 hasConceptScore W2022282235C121608353 @default.
• W2022282235 hasConceptScore W2022282235C126322002 @default.
• W2022282235 hasConceptScore W2022282235C126894567 @default.
• W2022282235 hasConceptScore W2022282235C141071460 @default.
• W2022282235 hasConceptScore W2022282235C142724271 @default.
• W2022282235 hasConceptScore W2022282235C170493617 @default.
• W2022282235 hasConceptScore W2022282235C204787440 @default.
• W2022282235 hasConceptScore W2022282235C27081682 @default.
• W2022282235 hasConceptScore W2022282235C2776235491 @default.
• W2022282235 hasConceptScore W2022282235C2779466945 @default.
• W2022282235 hasConceptScore W2022282235C2780152017 @default.
• W2022282235 hasConceptScore W2022282235C2781406297 @default.
• W2022282235 hasConceptScore W2022282235C509974204 @default.
• W2022282235 hasConceptScore W2022282235C71924100 @default.
• W2022282235 hasIssue "7" @default.
• W2022282235 hasLocation W20222822351 @default.
• W2022282235 hasLocation W20222822352 @default.
• W2022282235 hasOpenAccess W2022282235 @default.
• W2022282235 hasPrimaryLocation W20222822351 @default.
• W2022282235 hasRelatedWork W1888477076 @default.
• W2022282235 hasRelatedWork W2032157250 @default.
• W2022282235 hasRelatedWork W2043410635 @default.
• W2022282235 hasRelatedWork W2418143924 @default.
• W2022282235 hasRelatedWork W2777583152 @default.
• W2022282235 hasRelatedWork W2957009455 @default.
• W2022282235 hasRelatedWork W4230379269 @default.
• W2022282235 hasRelatedWork W4255881101 @default.

• next